Return to search

Etherna attracts Series B

Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding.

Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding. The investors included LSP, PMV, Boehringer Ingelheim Venture Fund, Fund+ and Omega Funds.

Source: Press Release